Navigation Links
PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
Date:9/12/2013

Increase treatment rates among milder forms of the disease 447 Pipeline Assessment 457.1 Overview 457.2 Promising drugs in clinical development 467.2.1 CF-101 478 Market Outlook 518.1 China 518.1.1 Forecast 518.1.2 Key Events 538.1.3 Drivers and Barriers 539 Appendix 559.1 Bibliography 559.2 Abbreviations 589.3 Methodology 609.4 Forecasting Methodology 609.4.1 Diagnosed DES patients 609.4.2 Percent Drug-treated Patients 619.4.3 Drugs Included in Each Therapeutic Class 619.4.4 General Pricing Assumptions 619.4.5 Individual Drug Assumptions 629.4.6 Generic Erosion 639.5 Physicians and Specialists Included in this Study 649.6 About the Authors 659.6.1 Author 659.6.2 Global Head of Healthcare 669.7 About GlobalData 679.8 Contact Us 679.9 Disclaimer 67

1.1 List of Tables Table 1: Symptoms of Dry Eye Syndrome 16

Table 2: Treatment Guidelines for Dry Eye Syndrome 24

Table 3: Commonly Prescribed Drugs for Dry Eye Syndrome by Class in the Global Markets, 2012 26

Table 4: Leading Treatments for Dry Eye Syndrome, 2012 29

Table 5: Product Profile – Diquas 31

Table 6: Diquas SWOT Analysis, 2012 33

Table 7: Summary of Minor Drug Classes, 2012 36

Table 8: Overall Unmet Needs – Current Level of Attainment 38

Table 9: Clinical Unmet Needs – Gap Analysis, 2012 43

Table 10: Dry Eye Syndrome – Phase Pipeline, 2012 46

Table 11: Comparison of Therapeutic Classes in Development for Dry Eye Syndrome, 2012 47

Table 12: Product Profile – CF101 48

Table 13: CF101 SWOT Analysis, 2012 50

Table 14: Sales Forecasts ($m) for Dry Eye Syndrome in China, 2012–2022 52

Table 15: Key Events Impacting Sales for Dry Eye Syndrome China, 2012–2022 53

Table 16: China, Dry Eye Syndrome Market – Drivers and Barriers, 2012–2022 53

1.2 List of Figures

Figur
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
6. Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
7. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
8. Psyadon Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
11. MEI Pharma Reports New Data Showing High Response Rates in Clinical Trial of Pracinostat and Azacitidine in Myelodysplastic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... from the Company,s Board of Directors in order to ... of Impax in 1995 and served as the Company,s ... April 2014. Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO ... Chief Executive Officer stated, "We wish to thank Larry ...
(Date:7/6/2015)... -- Akcea Therapeutics, a wholly-owned subsidiary of Isis ... that the U.S. Food and Drug Administration has ... ) for the treatment of patients with Familial ... disease characterized by extremely high triglyceride levels and ... published in the NEJM in December 2014, patients ...
(Date:7/6/2015)... /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... its board of directors has received a preliminary non-binding ... Zhang , chairman of the board of directors of ... investment vehicle wholly owned by Mr. Zhang(" Neptunus Holding ...
Breaking Medicine Technology:Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
... Rochester Medical Corporation (NASDAQ: ROCM ) will announce ... 2012.  The Company will then hold a quarterly conference call ... 3:30 p.m. central time (4:30 p.m. eastern time). ... be accessed at Rochester Medical,s website at www.rocm.com .  ...
...   Hospira, Inc. (NYSE: HSP ), the ... announced enrollment of the first patient in a Phase III ... III program, which follows a successful Phase I trial that ... EPO and the reference product, Amgen,s Epogen ® in ...
Cached Medicine Technology:Rochester Medical Announces First Quarter 2012 Earnings Conference Call, Wednesday, January 25, 2012 2Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 2Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 3
(Date:7/5/2015)... ... 2015 , ... Security Life Insurance Company of America, a ... of PrimeStar Individual Dental Insurance. Beginning now, enhancements include the expansion of our ... (MAC) and usual, customary and reasonable (UCR). , Whether consumers are looking ...
(Date:7/5/2015)... ... July 05, 2015 , ... Women’s Excellence in Wellness, ... Lake Orion location. The special consists of 2 months of unlimited classes for just ... Movestrong is located at 1410 South Lapeer Road in Lake Orion. ...
(Date:7/4/2015)... ... 2015 , ... Chronic Neck Pain. Neck pain is no small ... the neck. Another 19% suffer from head, migraine, or facial pain, in some cases ... of American workers must deal with neck pain. Strategies for mitigating neck ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon ... 2nd creating a buzz of media attention. In an effort to spread the ... Tiffany Hendricks. , "These days many people are feeling overwhelmed by stress and ...
(Date:7/3/2015)... ... , ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod ... . To be held from March 4th - 6th, the 2016 (a previous announcement ... Dallas. , Designed to take participants from the basic training and fundamentals of nasal ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3
... smoking greatly increases the risk that a blood vessel ... called an aneurysm which could be life-threatening if ... Stroke Association,s International Stroke Conference 2010. Researchers reported on ... project, a multinational collaboration funded by the National Institutes ...
... , , ... ... , , ... ...
... first one, number of teeth in first year , FRIDAY, ... in the first year of life have been identified by ... of 6,000 people in Finland and Britain who took part ... until adulthood. The scientists pinpointed five genes associated with the ...
... ... allows point-of-care workers to improve workflow and patient care. , ... (PRWEB) February 26, 2010 ... partnership with Voalt , a leading developer of innovative point-of-care communications software ...
... ... patients and asbestos exposure victims who are interested in learning more about clinical trials ... ... provide comprehensive resources for mesothelioma patients and their loved ones, including information about ...
... ... the public to spend two moonlit evenings basking in blissful meditations and looking at ... ... opportunity to explore life,s most fascinating questions at a most unexpected place, Tampa,s USF ...
Cached Medicine News:Health News:Smoking significantly increases risk of aneurysm in people with certain genes 2Health News:Smoking significantly increases risk of aneurysm in people with certain genes 3Health News:Landauer, Inc. Declares Regular Cash Dividend 2Health News:Genes Behind Tooth Development Discovered 2Health News:Connexall Announces Partnership with Voalt 2Health News:Connexall Announces Partnership with Voalt 3Health News:Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options 2Health News:Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options 3Health News:Explore, Love, Happiness, Life Purpose, and Destiny with World Renowned Yogi and Mystic, Sadhguru 2
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: